Therapeutic Intervention of Eriomin Associated With Metformin in the Control of Hyperglycemia in Pre-Diabetic Patients (Eriomin+Met)
Pre-diabetes
About this trial
This is an interventional treatment trial for Pre-diabetes focused on measuring citrus flavonoids, Eriomin, oral antidiabetic biguanide (metformin), hyperglycemia, microbiota
Eligibility Criteria
Inclusion Criteria: Glycemia of 6.1 to 7.0 mmol / L Glycated hemoglobin with values between 5.7 and 6.4% Exclusion Criteria: use of drugs, vitamins and dietary supplements, alcohol consumption (> 20 g alcohol/d), and intense physical activity (> 5 hours/week). History of cardiovascular disease, diabetes mellitus, liver, kidney or pancreatic disease
Sites / Locations
- Centro de Estudos e Praticas em Nutrição (CEPRAN)Recruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Eriomin/Placebo
Placebo/Eriomin
Group A will receive Eriomin (250 mg/day) for 12 weeks, followed by a 2-week washout period, and then placebo (250 mg/day) for 12 weeks.
Group B will receive placebo (250 mg/day) for 12 weeks, followed by a 2-week washout period, and then Eriomin (250 mg/day) for 12 weeks.